Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

jimmy18000 Feb. 19 at 7:51 PM

$CPIX cautiously optimistic we will get bread crumbs of DMD and IPF developments in the upcoming earnings report.

2 · Reply

haha1978 Feb. 19 at 7:01 AM

$CPIX ifetroban news out if canada 2/10. https://defeatduchenne.ca/cumberland-pharmaceuticals-update-on-a-potential-new-heart-treatment-for-duchenne/

0 · Reply

haha1978 Feb. 19 at 6:52 AM

$CPIX fda only requiring 1 study now for drug approval. This might set Ifetroban up if its deemed sufficient for DMD early approval. https://www.seattletimes.com/nation-world/nation-politics/fda-will-drop-two-study-requirement-for-new-drug-approvals-aiming-to-speed-access/

0 · Reply

haha1978 Feb. 19 at 1:23 AM

$CPIX ifetroban sclerosis study 34 patirnts is due 1H 2026. Its being completed this month.

0 · Reply

2pumps1dump Feb. 18 at 1:30 PM

$CPIX odd

1 · Reply

AlgoTwitch Feb. 17 at 3:56 PM

$CPIX Cumberland Pharmaceuticals markets niche hospital drugs, facing generic competition and portfolio diversification challenges.

0 · Reply

haha1978 Feb. 17 at 5:11 AM

$CPIX Looking for AA on ifetroban on P2 DMD OLE. Fingers crossed.

0 · Reply

EmproX Feb. 16 at 11:20 PM

$QNTM $APPS $CPIX $INKT 0{}

0 · Reply

OfficialStocktwitsUser Feb. 16 at 9:45 AM

$CPIX RSI: 54.25, MACD: -0.0513 Vol: 0.30, MA20: 3.94, MA50: 3.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioResearcher Feb. 14 at 5:28 PM

$CPIX Talicia is the ONLY drug that offers FULL refund if it does not cure after 14 days of treatment, that is one heck of confidence. Talicia is owned by an Israel company, it lacks sale force and channels, but now CPIX will change that, they will grow Talicia market in the future with their strong sale force. It is synergy.

1 · Reply

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Dec 8, 2025, 9:05 AM EST - 2 months ago

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 6:06 PM EST - 3 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:00 PM EST - 3 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Oct 28, 2025, 4:05 PM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 20, 2025, 9:05 AM EDT - 4 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 4 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 13, 2025, 9:05 AM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 1, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Sep 29, 2025, 9:05 AM EDT - 5 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 6, 2025, 1:52 AM EDT - 7 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 7 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 7 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 7 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 8 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 9 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 10, 2025, 4:23 AM EDT - 10 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 10 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 10 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 1 year ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 1 year ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 1 year ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 2 years ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 12, 2023, 4:21 AM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

jimmy18000 Feb. 19 at 7:51 PM

$CPIX cautiously optimistic we will get bread crumbs of DMD and IPF developments in the upcoming earnings report.

2 · Reply

haha1978 Feb. 19 at 7:01 AM

$CPIX ifetroban news out if canada 2/10. https://defeatduchenne.ca/cumberland-pharmaceuticals-update-on-a-potential-new-heart-treatment-for-duchenne/

0 · Reply

haha1978 Feb. 19 at 6:52 AM

0 · Reply

haha1978 Feb. 19 at 1:23 AM

$CPIX ifetroban sclerosis study 34 patirnts is due 1H 2026. Its being completed this month.

0 · Reply

2pumps1dump Feb. 18 at 1:30 PM

$CPIX odd

1 · Reply

AlgoTwitch Feb. 17 at 3:56 PM

$CPIX Cumberland Pharmaceuticals markets niche hospital drugs, facing generic competition and portfolio diversification challenges.

0 · Reply

haha1978 Feb. 17 at 5:11 AM

$CPIX Looking for AA on ifetroban on P2 DMD OLE. Fingers crossed.

0 · Reply

EmproX Feb. 16 at 11:20 PM

$QNTM $APPS $CPIX $INKT 0{}

0 · Reply

OfficialStocktwitsUser Feb. 16 at 9:45 AM

0 · Reply

BioResearcher Feb. 14 at 5:28 PM

1 · Reply

BioResearcher Feb. 14 at 5:13 PM

$CPIX Talicia is an expensive brand name drug (compared with other generics) but it is highly effective due to its delayed release technology, There are many praise of Talicia on Reddit, here is one of many:

0 · Reply

BioResearcher Feb. 14 at 4:44 PM

$CPIX It is a brand name drug that has proprietary delayed release technology costing $900 Now CPIX owns it and they will leverage their strong sale team and channels to market it.

0 · Reply

haha1978 Feb. 14 at 3:10 PM

$CPIX the triple combo antibiotic market for h plyori that talicia covers was estimated at 351 million market in 2022. We should get at least 40% of it at some point. https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

0 · Reply

BioResearcher Feb. 13 at 8:46 PM

$CPIX By granting Fast Track to Ifetroban, FDA acknowlges the potential of Ifetroban in DMD Cardio. An affordable treatment for ALL DMD patients, not just the rich patients. It will save Medicaid a ton of money compared to other expensive DMD drugs. It is DMD heart issue that kill DMD patients, not their loss of mobility.

0 · Reply

BioResearcher Feb. 13 at 8:26 PM

$CPIX FDA just want cheap drugs nowadays. Ifetroban is the ONLY drug that solely targets DMD Cardio. DMD Cardio is the leading cause of death in DMD patients, I believe FDA will help Ifetroban to reach the market as soon as they can because it should be very affordable. Kennedy's Medicaid is running out of money... Stay tuned for good news....

0 · Reply

BioResearcher Feb. 11 at 3:04 PM

$CPIX FDA knows that the ONLY affordable drug for DMD Cardio is ifetroban. It should be affordable for all DMD patients, not just the rich patients. It has proven safe even with long term treatment. Let's be patient and wait for more good news.

0 · Reply

BioResearcher Feb. 11 at 2:47 PM

$CPIX This rocket will take off anytime... There are many short term catalysts including earning report ! It is weird to look forward to ER for small biotech companies :-) But CPIX is special, very well-managed company with revenue stream.

0 · Reply

haha1978 Feb. 10 at 9:02 PM

$CPIX sadly this week is wasted with the inflation data and jobs and next week is a holiday. And after that probably a war in Iran but who cares. We are here for the drugs not bombs or ai. Best case its happening in March. Approaching the 1 year mark on my first batch of shares.

0 · Reply

haha1978 Feb. 10 at 5:13 PM

$CPIX IPD should blow it out the water. Lets see that p2 data.

0 · Reply

haha1978 Feb. 10 at 3:50 PM

$CPIX worrying too much about the laxative drug. Revenues are being replaced with the other 7 drugs. It did what 7 million thus year. Talicia is a 1 billion dollar per year H plyori treatment covered by ip protection till 2042. Thats 16 more years. Wait till sales are ramped yp there and it covers the 40% antibiotics resistance h plyori. Should be worth much more than a measily 7 million dollar a year laxative. I hope it ramps up to 20 millionthis year talicia.

0 · Reply

MomentumWatcher Feb. 10 at 3:07 PM

$CPIX is a pharmaceutical company (Cumberland Pharmaceuticals); niche portfolio facing generic competition.

1 · Reply

BioResearcher Feb. 6 at 8:24 PM

$CPIX Interesting, it turns out: 6 years ago, U. of Vanderbilt researchers have also found that Ifetroban can stop cancers from spreading independently in mice:

1 · Reply

Market Cap	57.58M
Revenue (ttm)	37.87M
Net Income (ttm)	-6.48M
EPS (ttm)	N/A
PE Ratio	48.50
Forward PE	N/A
Profit Margin	-17.11%
Debt to Equity Ratio	0.20

Volume	118,824
Avg Vol	230,420
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	86%
Beta	-0.52
Analysts	Strong Buy
Price Target	$8.50